AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Abcellera Biologics Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:03.840 and compliance officer. You may begin. 00:00:04.020 -- 00:00:09.120 Thank you. Hello, everyone. Thank you for joining us for Obscilla's 2025 second 00:00:09.120 -- 00:00:14.240 quarter earnings call. I'm Trent Steinmart, Obscilla's chief legal and compliance officer. 00:00:14.240 -- 00:00:19.540 Dr. Carl Hanson, Obscilla's president and CEO, and Andrew Booth, Obscilla's chief financial 00:00:19.540 -- 00:00:24.700 officer are also on the call. During today's call, we anticipate making projections and 00:00:24.700 -- 00:00:29.080 forward-looking statements based on our current expectations and following the safe harbor 00:00:29.080 -- 00:00:33.520 provisions of the Private Securities Litigation Reform Act of 1995. 00:00:33.520 -- 00:00:38.060 Our actual results may differ materially due to several factors outlined in our latest 00:00:38.060 -- 00:00:43.460 Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities Exchange 00:00:43.460 -- 00:00:44.960 Commission. 00:00:44.960 -- 00:00:49.300 Obscilla is not obligated to update any forward-looking statements, 00:00:49.300 -- 00:00:53.400 whether due to new information, future events, or otherwise. 00:00:53.400 -- 00:00:58.580 Our presentation today, including our earnings press release and SEC filings issued 00:00:58.580 -- 00:01:02.560 earlier today, are available on our Investor Relations website. 00:01:02.560 -- 00:01:06.420 The information we provide about our antibody therapy pipeline is for the benefit of 00:01:06.420 -- 00:01:10.080 the investment community is not intended to be promotional. 00:01:10.080 -- 00:01:14.400 As we transition to our prepared remarks, please note that all dollars referenced are 00:01:14.400 -- 00:01:19.510 U.S. dollars. After our prepared ...